Please watch the video at Investors.com - How To Buy Stocks: Flat Base Chart Pattern On Friday ... During the March quarter, Humira sales crashed 35.9% to $2.27 billion. But that still topped ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Shares in the pharma company fell more than 8% after it reported sales of immunology therapy Humira (adalimumab) came in at $3.5 billion – down 25% – while new therapies Skyrizi (risankizumab ...

Humira sales in 2024 were $9 billion, down 58% from their peak. The good news is that AbbVie has already found a replacement for Humira with two blockbuster drugs: Skyrizi and Rinvoq. While these ...

Humira is starting to feel the effects of lower-cost biosimilar competition in some markets however, with sales falling for the first time in the second quarter of this year. The FDA approval for ...

These two drugs are increasingly important as they help offset the decline in Humira sales due to biosimilar competition. Analysts project that Skyrizi and Rinvoq could potentially absorb a ...

The company's immunology drugs, Skyrizi and Rinvoq, exceeded sales forecasts by 5% and 8%, respectively, effectively compensating for the 13% decline in Humira sales. This performance underscores ...